Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated
antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011
for advanced melanoma on the basis of survival benefit. Since that time, we have made …

Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been …

Background In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated
antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody …

Tumor-derived exosomes are emerging mediators of tumorigenesis. We explored the function
of melanoma-derived exosomes in the formation of primary tumors and metastases in …

Background Nivolumab combined with ipilimumab resulted in longer progression-free survival
and a higher objective response rate than ipilimumab alone in a phase 3 trial involving …

<p id="p001">The abscopal effect is a phenomenon in which local radiotherapy is associated
with the regression of metastatic cancer at a distance from the irradiated site. The abscopal …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

Proposed origins of pelvic serous carcinoma include the ovary, fallopian tube, and peritoneum.
Prophylactic salpingo-oophorectomies in BRCA+ women have recently identified the …